Tin tức & Cập nhật
Lọc theo Chuyên ngành:
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
Surveillance of favourable-risk patients with metastatic renal cell carcinoma (mRCC) using risk stratification based on the International mRCC Database Consortium (IMDC) and number of metastatic sites may be done following cytoreductive nephrectomy without initiating systemic therapy, suggests a recent study.
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
30 Jul 2023Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023Niraparib maintenance confers prolonged survival in advanced ovarian cancer
Maintenance therapy with niraparib appears to increase progression-free survival (PFS) in patients with advanced ovarian cancer, irrespective of postoperative residual disease or biomarker status, according to data from the phase III PRIME study.
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
27 Jul 2023Intranasal vardenafil works faster than oral formulation for ED
Vardenafil (VDF), an effective treatment for erectile dysfunction, administered by an intranasal spray formulation achieves faster but similar plasma concentration with only about one-third dose relative to oral VDF tablet, according to a study.
Intranasal vardenafil works faster than oral formulation for ED
26 Jul 2023Cilta-cel a new Soc for lenalidomide-refractory MM?
In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.